US Senators challenge Sanofi and others about insulin


Two powerful US senators opened a study on rising insulin prices on Friday asking three laboratories, including Sanofi, France, to provide explanations.

Republic Senator Chuck Grassley, chairman of the Senate Finance Committee, and Ron Wyden, the senior city senator in this committee, wrote letters to leaders of Eli Lilly, Novo Nordisk and Sanofi on this product.

Senators point to the significant rise in prices they see in similar proportions from the three workshops.

He takes the example of insulin Eli Lilly, Humalog, whose price moved from $ 35 to $ 234 between 2001 and 2015, an increase of 585%.

Diabetes spreads around the world and feeds a record of insulin demand.

The two senators have asked the three laboratories in particular for information on research, development and production costs as well as on insulin sales.

Yasmeen Abutaleb, Patrick Vignal for French service


Source link